




13 1







15 1







17 18












21 22





23 24



Conclusions 2021

- The Good
 - OCT angiography can detect decreased capillary vessel density within the peripapillary nerve fiber layer and macula in patients with suspected glaucoma, preperimetric glaucoma, and perimetric glaucoma.
 - The degree of vessel density loss correlates significantly with glaucoma severity
 - Choroidal or deep-layer microvasculature dropout as measured by OCTA is also associated with glaucoma damage.
 - Lower peripapillary and macular vessel density and choroidal microvasculature dropout are associated with faster rates of disease progression.



25 26

The Bad

For differentiating glaucomatous from healthy eyes, some studies found that peripapillary and macular vessel density measurements by OCTA show a diagnostic ability (area under the receiver operating characteristic curve) that is comparable with structural OCT retinal nerve fiber and ganglion cell thickness measurements, whereas other studies found that structural OCT measurements perform better.



And the Ugly

Artifacts and Image Quality: The report notes that OCTA is prone to motion artifacts and can be sensitive to patient movement, which may affect image quality. This limitation needs to be considered when interpreting OCTA results.

Lack of Longitudinal Data: While OCTA shows promise, the report highlights the need for more longitudinal studies to fully understand its utility in long-term glaucoma management.



27 28


OCT-A may be more helpful than OCT in determining fast progressors


Anous Control of History Control of Commons of History (Angue and History Control of Hist


- Faster VD loss during the initial follow-up period was associated with faster concurrent and subsequent rates of VF loss during the extended period.
- The association was stronger for the OCTA model than for the OCT model.
- Nishida T, Moghimi S, Wu JH, Chang AC, Diniz-Filho A, Kamalipour A, Zangwill LM, Weinreb RN. Association of initial optical coherence tomography angiography vescel density loss with faster visual field loss in glaucoma. JAMA ophthalmology. 2022 Apr 1;140(4):319-26.

Choroidal Microvascular Dropout


29 30






























39 40







41 42













45 4







47 48









51

OCT-A, Macular Vessel Density and Glaucoma

139 eyes(23 healthy eyes, 36 pre-perimetric glaucoma eyes, and 80 POAG eyes) of 94 patients who had at least 3 visits. The mean follow-up was 2.0 years for healthy eyes, 2.6 years for pre-perimetric glaucoma eyes, and 2.6 years for POAG eyes

In POAG eyes, macula vessel density decrease was faster than GCC thinning and associated with severity of disease.

Hou H, Moghimi S, Proudfoot JA, Ghahari E, Penteado RC, Bowd C, Yang D, Weinreb RN. Ganglion cell complex thickness and macular vessel density loss in primary open-angle glaucoma. Ophthalmology, 2020 Aug 1;127(8):1043-52.


Improved Blood Flow/Glaucoma Reversible?
Increase in the OCT angiographic peripapillary vessel density by ROCK inhibitor ripasudil instillation: a comparison with brimonidine


Etwo Chihara Godalina Dimitrova Tomoyuki Chihara Market Stance, vasodilate vessels, and may improve microcirculation to the ONH/have neuroprotective activity 1.2

Netarsudil is a ROCK/Norepinephrine transporter inhibitor Netarsudil is a ROCK/Norepinephrine transporter inhibitor Netarsudil additionally reduces aqueous production and lowers EVP Prospective study-Ripasudil enhanced peripapillary VD in POAG and OH Brimonidine did NOT Study on Tafluprost and Tafluprost/Timolol showed no change to VD3


1)Chihara E, et al. Clin Exp Ophthalmol. 2018;256:1257-12642)Tanna A, Johnson M. Ophthalmology. 2018;125:1741-1756
3)Kurysheva NI. Tolwan J Ophthalmol. 2019;939:399


53 54







55






57 58







59 60





61







63 64







65 66











69 70





71 72